Based on the aggregated intelligence of 170,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, pharmaceutical giant GlaxoSmithKline
With that in mind, let's take a closer look at Glaxo's business and see what CAPS investors are saying about the stock right now.
|Headquarters (Founded)||Brentford, U.K. (1935)|
|Market Cap||$101.8 billion|
|Trailing-12-Month Revenue||$46.6 billion|
CEO Andrew Witty (since May 2008)
CFO Simon Dingemans (since March 2011)
|Return on Equity (Average, Past 3 Years)||43.1%|
|Cash/Debt||$10.2 billion / $24.8 billion|
Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.
Less than two months ago, andycheung2000 listed several of Glaxo's positives: "Excellent management. Solid balance sheet. Strong consumer health care, especially in emerging markets. Very strong vaccines division. Doesn't have too many patents expiry issues. Best drugs pipeline of the major pharmaceuticals. Great dividend."
Over the next five years, in fact, Glaxo is expected to grow its bottom line at a solid rate of 11.2% annually. That's much faster than rivals Merck (4.5%), Novartis (4.7%), and Pfizer (2.7%).
CAPS member cllqmb expands on Glaxo's recent lupus treatment approval as a tasty opportunity:
FDA approval of BENLYSTA will bring profits from US markets and European approval is on the way later this year. Revenues are going to increase immensely over the next few years and unless there is a drug approval that will compete with the current monopolistic standing of this new drug, both [Human Genome Sciences] and Glaxosmithkline will do extremely well.
What do you think about Glaxo, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!